bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: S A J J M A M F J
2013: D N O S

 
  Other news for:
Technology, Medical
Transplants
 Resources from HONselect
New Blood Test May Help Detect Heart Transplant Rejection
It might one day spare patients from invasive biopsies, study says

By Robert Preidt

WEDNESDAY, June 18, 2014 (HealthDay News) -- Researchers say they've developed a blood test that can detect heart transplant rejection weeks or months earlier than previously possible.

The test looks for increasing amounts of the heart donor's DNA in the blood of the transplant recipient. Unlike a biopsy, this noninvasive test does not require removal of any heart tissue, Stanford University researchers said.

"This test appears to be safer, cheaper and more accurate than a heart biopsy, which is the current gold standard to detect and monitor heart-transplant rejection," study co-senior author Stephen Quake, professor of bioengineering and applied physics, said in a university news release. "We believe it's likely to be very useful in the clinic."

Transplant recipients who show early signs of rejection can be given anti-rejection drugs in an effort to reduce the immune system's attack on the transplanted organ.

Currently, heart transplant patients have to undergo dozens of heart biopsies in the months and years after they receive their new heart. The biopsies are uncomfortable and may cause complications such as heart rhythm problems or heart valve damage, the researchers said.

The new test -- called a cell-free DNA test -- proved effective in a study of 44 adults and 21 children who had heart transplants. The test accurately detected rejection in 24 patients who suffered moderate to severe rejection, including one who required a second heart transplant, the researchers said.

The test was able to detect signs of rejection up to five months before biopsies showed any signs of trouble, according to the study published June 18 in the journal Science Translational Medicine.

"We've found that this cell-free DNA [test] is a very accurate way to diagnose acute rejection, sometimes weeks to months before a biopsy picks up any signs," study co-senior author Dr. Kiran Khush, an assistant professor of medicine at Stanford, said in the news release. "This earlier detection may prevent irreversible damage to the transplanted organ."

The new test is different from another blood test used to detect transplant rejection. That test is called AlloMap and it checks for immune system genes involved in rejection. The cell-free DNA test outperformed AlloMap by a wide margin, according to the Stanford team.

The researchers noted that there's still a great deal of work to be done before this cell-free DNA test could become commercially available.

More information

The U.S. National Library of Medicine has more about heart transplantation.

SOURCE: Stanford University, news release, June 18, 2014

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=688921

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Heart
Rejection (Psychology)
Transplants
Blood
Hematologic Tests
Biopsy
DNA
Research Personnel
Transplantation
Immune System
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact